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Abstract 
 
This study examined the effect of exercise-induced muscle damage (EIMD) 
elicited by a bout of plyometrics on outdoor running performance. Seventeen 
males (mean ± SD: age 37 ± 8 years, height 180 ± 5.3 cm, body mass 75.4 ± 7.5 
kg) were recruited from running and triathlon clubs within Cheshire. They were 
randomly assigned to the treatment (n = 8) or control group (n = 9) with the study 
adopting a randomized, controlled, repeated measures design. Before and 48 
hours after treatment the subjects underwent testing on EIMD markers (muscle 
thigh circumference, muscle function and muscle soreness) and ran a 5 km 
outdoor time-trial. During the time-trial speed, heart rate and RPE were measured 
at each kilometre along with blood lactate at the finish. On completion of the 5 km 
run the treatment group completed a bout of 10 x 10 drop jumps from a 35 cm 
bench to elicit EIMD. Multiple independent t-tests along with multiple two-way and 
three-way ANOVAs were used for analysis. Muscle soreness significantly 
increased within the treatment group after EIMD (p<0.05), however no significant 
change occurred in muscle circumference and force production (p>0.05). During 
the time-trial RPE, heart rate, average running speed and blood lactate did not 
significantly change in the treatment group (p>0.05). Although average running 
speed did not significantly change, a decrease was observed with a significantly 
slower time-trial completion times between the two groups (p<0.05). In conclusion, 
EIMD significantly affects endurance performance among well-trained athletes 
through an altered perception of effort. 
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1 
Introduction 
The completion of unaccustomed eccentric muscular contractions, identified by a 
simultaneous lengthening and contraction of the muscle, has been identified as 
the primary cause of exercise-induced muscle damage (EIMD; Falvo & Bloomer, 
2006; Tee, Bosch & Lambert, 2007). Eccentric muscular contractions cause EIMD 
through mechanical and metabolic mechanisms, with mechanical identified as the 
primary cause (Byrne, Twist & Eston, 2004) associated with a reduced fibre 
recruitment and high force production (Enoka, 1996; Falvo & Bloomer, 2006).  The 
ability of the muscle to produce high force during eccentric contractions is 
attributable to the mechanical detachment of cross bridges in comparison to 
concentric actions where adenosine tri-phosphate (ATP) is utilised (Byrne et al., 
2004; Eston, Byrne & Twist, 2003). This detachment of cross bridges causes 
disruption to the sarcomeres resulting in the muscle adopting a shorter length to 
enable a similar level of force to be produced (Byrne et al., 2004) coupled with a 
detrimental effect on the excitation-coupling system (Eston et al., 2003). The 
severity of EIMD is significantly influenced by the intensity and volume of the 
physical activity that athletes undertake (Clarkson & Hubal, 2002) along with 
whether the athlete is unaccustomed to the exercise bout (Tee et al., 2007). If the 
athlete has previous experience of eccentric training the severity of EIMD is 
reduced due to a protective mechanism referred to as ‘repeated bout effect’ (Eston 
et al., 2003; Falvo & Bloomer, 2006). Once an athlete has completed a bout of 
eccentric training the body adapts to prevent such high levels of EIMD on 
completion of subsequent bouts. A range of mechanisms have been proposed to 
underlie this theory including mechanical, cellular and neural however these 
mechanisms are not well understood (McHugh, 2003). 
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It is well documented that numerous symptoms are associated with EIMD, 
including delayed onset muscle soreness (DOMS), reduced force production, 
increase in limb circumference, increase creatine kinase (CK) levels, stiffness, 
reduced range of motion, damage to the structural aspects of the muscle and 
reduced strength (Byrne et al., 2004; Chen, Nosaka, Lin, Chen & Wu, 2009; Eston 
et al., 2003; Tee, Bosch & Lambert, 2007). The measuring of force production to 
assess the functional capability of the athlete is of greatest importance and has 
the greatest transfer to the applied setting. Previous research has identified the 
time course for peak muscle damage and recovery is individual and differs among 
markers, with DOMS peaking between 24-48 hours, swelling at 48 hours and force 
production taking up to 7 days to recover (Byrne et al., 2004; Falvo & Bloomer, 
2006; Komi & Viitasalo, 1977). A range of direct and indirect measures including; 
muscle biopsy and Likert scales have been utilised in research to monitor the 
symptoms of EIMD (Warren, Lowe & Armstrong, 1999).  
In recent years endurance athletes have begun utilising plyometrics as a training 
method to improve their performance. It is believed that plyometric exercise elicits 
improvements in power production (Spurrs, Murphy & Watsford, 2003) a 
physiological characteristic that might limit endurance performance (Noakes, 
1998). Running economy appears to be the physiological characteristic with the 
greatest plasticity to the exposure of plyometrics resulting in the significant 
improvements in running performance (Markovic & Mikulic, 2010). An enhanced 
running economy has been associated with improvements in race times and 
illustrates the applied benefits of endurance athletes incorporating plyometrics into 
their training regime (Paavolainen, Hakkinen, Hamalainen, Nummela & Rusko, 
1999; Spurrs, Murphy & Watsford, 2003). However the nature of plyometrics 
means that they often elicit symptoms of EIMD in the days after their application 
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(Burt & Twist, 2011; Jamurtas et al., 2000; Marcora & Bosio, 2007). Therefore it is 
imperative athletes and coaches are aware of the impact such training has on 
subsequent performance as plyometrics performed at a high intensity result in 
elevated neuromuscular and central nervous system stress that might impair 
endurance performance (Burt & Twist, 2011).  
The ability to measure EIMD and understand its impact on endurance 
performance per se is crucial. Studies have researched the effects of EIMD on 
endurance performance per se. Previous research has conclusively found EIMD to 
significantly reduce the distance covered during time-trials in running using 
moderately trained participants (Marcora & Bosio, 2007) and cycling in 
recreational participants (Burt & Twist, 2011; Twist & Eston, 2009). Findings 
regarding the effect of EIMD on varying physiological measures during endurance 
performance are conflicting among studies. Burt & Twist (2011) reported a 
significant decrease in heart rate and minute ventilation (VE), however these 
measures remained unchanged during time-trials in Marcora & Bosio (2007) and 
Twist & Eston (2009) studies. The effect of EIMD on blood lactate is also not 
consistent among research with two studies in cycling reporting a decrease at 48 
hours (Burt & Twist, 2007; Twist & Eston, 2009) and no change at 48 hours during 
a running protocol (Marcora & Bosio, 2007). Current research has reported 
significant changes in rate of perceived exertion (RPE) during time-trials proposing 
EIMD alters the participant’s perception of effort (Marcora & Bosio, 2007; Twist & 
Eston, 2009). A possible explanation for this altered perception could be as a 
result of the elevated muscle soreness that occurs after the completion of 
eccentric exercise (Proske, Weerakkody, Percival, Morgan, Gregory & Canny, 
2003). A more recent study by Burt & Twist (2011) found that a bout of eccentric 
exercise eliciting EIMD did not alter the participant’s perception responses. These 
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differences could have occurred due to the differing time-trial protocols with Burt & 
Twist (2011) using 15 minute duration, Twist & Eston (2009) who used 5 minute 
duration and Marcora & Bosio (2007) who used a 30 minute time-trial. These 
contrasting protocols will have significantly affected the pacing strategy adopted 
and subsequently the perception of effort, with shorter time-trials requiring a 
greater power output in comparison to the maintenance of a slightly reduced 
power output over longer time-trials (Van Ingen Schenau, De Koning & De Groot, 
1992). 
However despite these findings providing a good starting point when looking into 
the effects of EIMD on endurance performance, all were based in a controlled 
laboratory setting. The surface and gradient have been identified as two variables 
that can significantly influence the pacing strategies adopted and the subsequent 
performance (Faulkner et al, 2008; Howatson & Milak, 2009). Therefore 
conducting research outdoors will allow these variables to be present, potentially 
providing innovative findings that coaches and athletes can apply to their training 
to improve their endurance performance. This is important as athlete’s train and 
compete outdoors, not in a laboratory where the environment is stable. 
There is no current research assessing the effect of EIMD on endurance 
performance using real-world performance scenarios. Furthermore the effects of 
EIMD on trained athletes is less well understood due to the reluctance of this 
group to participate in such research studies for fear of impairing performance 
(Falvo & Bloomer, 2006). Therefore this study will aim to identify the effect of 
EIMD on outdoor running performance in well-trained athletes. It is hypothesized 
that EIMD will impair 5 km running performance, specifically via an altered 
perception of effort with a reduction in running speed and no change in RPE. 
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Method 
Participants  
Seventeen (mean ± SD: age 37 ± 8 years, height 180 ± 5.3 cm, body mass 75.4 ± 
7.5 kg) males classified as ‘well-trained’ were recruited to participate in the study 
from the running and triathlon clubs within Cheshire. In order to meet the ‘well-
trained’ criteria, each participant was required to have run at least 30 minutes, 
three times a week for the previous 6 months. Females were excluded from 
participation within the study to reduce the possibility of sex-related variables 
influencing the findings (Eston et al., 2003). 
The participants were provided with a participant information sheet (appendix B) 
and instructed to complete an informed consent form (appendix A) and health 
questionnaire (appendix C) prior to participating.  
The study was approved by the Faculty of Applied Sciences Research Ethics 
Committee at the University of Chester. 
The sample size was calculated using GPower3.1 (v.21, SPSS Inc., Chicago, IL, 
USA) based on an effect size statistic of 0.62 derived from the results from the 
study by Marcora & Bosio (2007), and using an error probability = 0.05 and, power 
= 0.8. 
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Design 
The study employed a randomized, controlled, repeated measures design 
(Figure.1). Each participant was randomly allocated to the control (no damage) or 
treatment (muscle damage) group. Running performance was the dependent 
variable with muscle damage the independent variable. Each participant was 
required to attend the University of Chester on three occasions. On the first visit 
the participants completed an incremental test on a treadmill to identify VO2peak 
along with measurements of stature and body mass. Participants also completed a 
familiarization trial on the isokinetic dynamometer to reduce the potential of a 
learning effect occurring during subsequent trials (Burt & Twist, 2011). The 
participants then returned between 24 hours to 2 weeks later and completed the 
first trial. On arrival the three muscle damage markers; muscle function, delayed-
onset muscle soreness (DOMS) and muscle thigh circumference were measured 
prior to the warm up. A 10 minute warm up preceded the outdoor 5 km time-trial 
run. On completion of the time-trial, the muscle damage protocol was completed 
by those allocated to the treatment group. Forty-eight hours later, the participants 
returned for the third and final visit. During this visit the same protocol as used in 
the second visit was repeated without the muscle damaging protocol. The decision 
to schedule the third visit 48 hours after the muscle damage protocol was based 
on previous research identifying that muscle damage markers peak between 24-
72 hours (Tee et al., 2007). Participants were asked to refrain from participating in 
strenuous exercise 24 hours prior to their first visit and refrain from any form of 
exercise between their second and third visit. They were also asked to avoid using 
anti-inflammatory or analgesic agents. 
 
7 
 
 
8 
Procedures  
Assessment of VO2peak 
The participant’s stature and body mass was measured with them in their 
underwear using a wall mounted stadiometer (Harpenden, Wall mounted, Holtain, 
Crymych, Dyfed, UK) and digital scales (Tanita, BWB-800, Tanita corporation, 
Tokyo, Japan) respectively. The participants then completed an incremental 
VO2peak test on a motor-driven treadmill (Woodway, PPS 55sport-I, GmbH, 
Germany), with the incline set at 1%. Each participant was instructed to complete 
a 10 minute warm up progressively increasing the intensity prior to commencing 
the test. The test began at 12 km·h-1 increasing by 1 km·h-1 at 3 minute 
increments until the participant reached exhaustion. Throughout the test expired 
air was collected using an online metabolic system (Viasys, Oxycon Pro, Viasys 
Healthcare, Hoechberg, Germany), which was be calibrated prior to each test. At 
the end of each 3 minute stage, heart rate (Polar FS1, Polar Electro, Oy, Finland), 
blood lactate (Lactate Pro, Arkray, Kyoto, Japan) and rate of perceived exertion 
(Borg, 1998) was recorded.  
Outdoor 5 km time-trial 
Each participant was instructed to complete a 10 minute standardized warm up 
comprising jogging and mobility exercises prior to commencing the time-trial. On 
completion of the warm up, a 5 Hz global positioning unit (GPS; SPI-Pro, 
GPSports, Canberra, Australia) was attached to the participant along with a heart 
rate monitor and an RPE chart with a pen to their wrist (Figure. 2). The GPS was 
fitted into a pocket on the back of a vest and used to record running speed and 
distance. The GPS has been shown to possess good reliability for these 
measures. 
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Figure 2: An example of the RPE chart used to record the athletes RPE at each km as used by Faulkner et al., (2008). 
The run followed an out and back course, with the participants running for 2.5 km 
before turning around and running 2.5 km back to the start on an undulating 
concrete surface. At 1 km checkpoints the participants were required to mark the 
chart with their current RPE (Faulkner et al, 2008), which together with the data 
generated from the GPS device was used to measure running performance. The 
participants were encouraged to complete the 5 km time-trial as fast as possible. 
On completion of the time-trial, a blood sample was taken from the fingertip and 
analysed for blood lactate concentration (Lactate Pro, Arkray, Japan).  
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Visit 3 
Experimental treatment 
The muscle damaging protocol involved the participant performing 10 sets of 10 
drop jumps from a 35 cm box, with a 1 minute rest period between each set. An 
infrared timing system (Optojump, Microgate S.r.1., Bolzano, Italy) was used to 
assess a maximal drop jump prior to each participant commencing the protocol. 
The participant was then instructed to aim to achieve this height throughout the 
protocol. Each jump was performed with the participant dropping from the box with 
hands on their hips, landing on the floor with both feet, squatting to approximately 
90° angle at the knee then jumping as high as possible. Evidence of muscle 
damage has been achieved through similar protocols in previous research (Burt & 
Twist, 2011; Marcora & Bosio, 2007). 
Muscular force production 
An isokinetic dynamometer (Biodex, Multi-joint System 3, Biodex Medical, New 
York, USA) was used to assess muscular force production of the participant’s 
dominant leg. Prior familiarization consisted of setting up the correct position 
allowing the participants to get used to the secure nature of the dynamometer 
whilst completing two sets of five knee extensions and flexion’s. The participants 
were seated in an upright position with a 90° angle at the knee and hip with the 
ankles securely fastened to the dynamometer arm. The participants were 
instructed to apply maximal force to the ankle pad in both the extension and 
flexion phase. Each participant completed 3 submaximal warm-up efforts at 50% 
of maximum prior to 5 maximal efforts at 60°·s-1 of which the highest value was be 
recorded. 
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Delayed onset muscle soreness (DOMS)  
Each participant was instructed to rate their perceived muscle soreness on the 
seven-point likert scale (Vickers, 2001). The scale ranges from 0-6 with each 
rating corresponding to a descriptive phrase. Participants were required to rate 
muscle soreness in the quadriceps, hamstrings and gastrocnemius, with these 
muscles commonly perceived as sore post eccentric exercise (Howatson & Milak, 
2009). 
 
0 – A complete absence of soreness 
1 – A light pain felt only when touched/a vague ache 
2 – A moderate pain felt only when touched/a slight persistent pain 
3 – A light pain when walking up and down stairs 
4 – A light pain when walking on a flat surface/painful 
5 – A moderate pain, stiffness, or weakness when walking/very painful 
6 – A severe pain that limits my ability to move 
Muscle circumference 
Muscle circumference was measured using a tape measure at mid-thigh, defined 
as the midpoint between the superior ridge of the patella and the crease of the 
groin. To ensure the mid-point was consistent throughout the trials, it was 
indicated using a marker pen. Three measurements were recorded per participant, 
with the average measurement used for statistical analysis. 
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Statistical analysis  
All data are presented as mean ± standard deviation (SD) and were analysed 
using SPSS (v.20, IBM SPSS Statistics, Chicago, IL, USA) with a p-level of 0.05. 
Prior to conducting further statistical tests the data was checked for normal 
distribution and equal variances using a Shapiro wilk test and levene’s test 
respectively. Multiple independent t-tests were then performed to assess any 
existing differences within baseline measures between the experimental and 
control group. To assess changes in performance, muscle damage, physiological 
and perceptual measures, multiple two-way (group [2] x test [2]) ANOVAs with 
repeated measures were conducted. Multiple three-way (group [2] x test [2] x time 
[2]) ANOVAs with repeated measures were carried out to analyse changes in 
speed, time of completion and RPE. If changes were present on completion of the 
ANOVAs, t-tests were used with a Bonferoni adjustment to identify where the 
differences occurred. 
Results 
Independent t-tests demonstrate that the allocation of participants to the treatment 
and control groups was successful in forming two groups of similar ability. 
Table 1. Treatment and control subject’s descriptive characteristics 
   Treatment (n=8)              Control (n=9) 
Age (y)         35 ± 8                       39 ± 7 
Stature (cm)    181.3 ± 4.1  178.8 ± 6.1 
Body Mass (kg)      76.4 ± 9.7    74.5 ± 5.3 
VO2 Peak (ml∙kg⁻¹∙min⁻¹)      59.5 ± 6.5    58.1 ± 2.8 
Values are presented as mean ± SD.  
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Muscle damage markers 
Interaction effects of group x time on muscle soreness revealed increases at 48 
hours in the hamstring (F=8.726, p=0.01) and gastrocnemius (F=4.764, p=0.045) 
for the treatment group after the damaging protocol. Soreness in the quadriceps 
was not different over time between the groups (F=0.706, p=0.414). There was no 
difference in muscle circumference over time between the groups (F=0.506, 
p=0.488) suggesting minimal muscle swelling occurred. There was no significant 
interaction of group x time for flexion (F=2.148, p=0.163) and extension (F=2.592, 
p=0.128) at 48 hours. However the treatment groups force production decreased 
from (99.0 ± 9.1to 94.2 ± 13.9N·m) for flexion and (184.6 ± 17.3 to 176.9 ± 
27.6N·m) for extension between pre and post, whilst the control groups force 
production increased (Table 2).  
Table 2. Effect of experimental treatment on muscle damage markers 
Variable  Group  Pre  Post   P 
DOMS Quad  EIMD  0.38 ± 0.744  2.00 ± 1.690  0.414 
Control  0.33 ± 1.000  1.22 ± 1.922 
DOMS Ham  EIMD  0.88 ± 0.991  3.00 ± 1.690  0.01 
Control  0  0 
DOMS Gastrocnemius  EIMD  0.50 ± 1.069  2.38 ± 2.264  0.045 
Control  0.89 ± 1.833  1.11 ± 2.421 
Muscle Circumference (cm)  EIMD  53.31 ± 3.515  52.69 ± 4.543  0.488 
Control  53.39 ± 3.140  53.22 ± 3.032 
Force Production Extension 
(N∙m) 
EIMD  184.6 ± 17.3  176.9 ± 27.6  0.128 
Control  194.3 ± 28.0  202.0 ± 30.4 
Force Production Flexion 
(N∙m) 
EIMD  99.0 ± 9.1  94.2 ± 13.9  0.163 
Control  104.2 ± 18.1  104.7 ± 20.6 
Values are presented as mean ± SD. P-values refer to the trial x group interaction of two-way 
ANOVA with repeated measures. DOMS=delayed onset muscle soreness, Quad=quadriceps, 
Ham=hamstring. 
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Physiological responses and performance measure 
There was no significant interaction of group x time for average heart rate 
(F=0.559, p=0.466), average RPE (F=0.175, p=0.682), average running speed 
(F=1.469, p=0.244) and post time-trial blood lactate concentration (F=3.275, 
p=0.09). Although no significant interaction occurred (F=1.469, p=0.244), average 
running speed decreased non-significantly by half a kilometre from 13.1 ± 1.7 to 
12.5 ± 2.7km·h⁻¹ for the treatment group between pre and post. In comparison, the 
control group ran marginally quicker 13.5 ± 0.9 to 13.7 ± 0.7km·h⁻¹ (Table 3, 
Figure 2), however it was not significant. Interaction effects of group x time on 5 
km time-trial completion time revealed increases at 48 hours (F=8.975, p=0.009, 
figure1) for the treatment group after the damaging protocol. 
Table 3. Changes in physiological variables after EIMD 
Values are presented as mean ± SD. P-values refer to the trial x group interaction of 2-way 
ANOVA with repeated measures. RPE=rate of perceived exertion. 
 
 
Variable  Group  Pre Test        Post Test       P 
Average Heart Rate (bpm)  EIMD  168.88 ± 8.008  170.50 ± 8.718  0.466 
Control 169.78 ± 12.647  174.44 ± 11.631 
Average RPE  EIMD  16.38 ± 1.061  16.13 ± 1.458  0.682 
Control 15.67 ± 1.225  15.22 ± 1.093 
Average Running Speed (km∙h⁻¹)  EIMD  13.050 ± 1.7188  12.475 ± 2.7364  0.244 
Control 13.478 ± 0.9458  13.711 ± 0.6864 
Completion Blood Lactate 
(mmol∙l⁻¹) 
EIMD  9.43 ± 1.528  9.650 ± 1.7138  0.09 
Control 8.61 ± 2.079  7.411 ± 1.8401 
5 km Completion Time (min)  EIMD  21.3 ± 1.9  22.2 ± 2.1  0.009 
Control 21.8 ± 1.5  21.6 ± 1.1 
15 
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Analysis of heart rate and RPE for each kilometre of the time-trial did not reveal an 
interaction effect of group x time x distance (F=1.364, p=0.27 & F=0.668, p=0.617 
respectively). Interaction effects of group x time x distance revealed a significant 
interaction between the treatment and control group at each kilometre (F=2.807, 
p=0.003). 
Discussion 
Speed 
The key finding of this study was the treatment group, who completed a bout of 
plyometrics to elicit muscle damage, ran the 5 km at a lower speed as 
hypothesized resulting in a significantly slower completion time equating to a 4% 
change in comparison to those who did not perform plyometrics. These findings 
are in agreement with Marcora & Bosio (2007) and Burt & Twist (2011) who both 
found that participants with EIMD completed a shorter distance during a specific 
time period in running with moderately trained individuals and cycling with 
recreational individuals respectively. As this study was conducted outside, the 
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participants encountered differing surfaces and gradients that could have led to 
contrasting findings compared to the previous research that has been conducted 
within a laboratory however this was not the case and suggests that the surface 
and gradient had no significant effect on running speed. These findings illustrates 
that participants who are well-trained still experience impaired endurance 
performance outdoors after a bout of eccentric exercise eliciting EIMD. Therefore 
careful consideration should occur when programming exercises such as 
plyometrics into an athlete’s training programme as their performance will be 
affected for at least 48 hours. 
RPE 
Although the participants ran at a reduced speed during the time-trial their 
perception of effort remained unchanged, agreeing with the findings of Burt & 
Twist (2011), Marcora & Bosio (2007) and Twist & Eston (2009). This means that 
the participants perceived their effort to be of a similar level for a reduced intensity 
illustrating that EIMD altered their perception responses. This supports the 
hypothesis for the study, and illustrates that these findings are consistent with 
previous research using varying protocols with time-trial distances varying from 5 
to 30 minutes. When performing shorter time-trials a greater power output is 
typically produced resulting in a higher RPE, whereas when performing a time-trial 
over a more prolonged period of time the power output will be slightly lower 
resulting in a reduced RPE to ensure they can complete the distance (Van Ingen 
Schenau et al, 1992). The experience of the participants within this study could 
have affected the findings as those with greater experience will likely have 
completed more time-trials and have a better understanding of their body’s ability 
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and the optimum pacing strategy to adopt (Abbiss & Laursen, 2008), however this 
does not seem to be the case. 
Heart rate 
Analogous to the findings of Marcora & Bosio (2007) and Twist & Eston (2009) 
EIMD had no significant effect on heart rate, which is in contrast to Burt & Twist 
(2011) who found a significant decrease in heart rate under EIMD. The vast 
majority of research including the findings from this study, suggest that 
cardiorespiratory responses are not a primary cause of impaired endurance 
performance in the presence of EIMD.   
Muscle Damage Markers   
Elevated levels of muscle soreness were found among those who completed the 
bout of plyometrics; however no significant change occurred in both force 
production and muscle circumference. This illustrates that although the muscle 
damaging protocol elicited muscle soreness, the functional capability of the 
athletes was not affected. These findings are in contrast to the vast majority of 
research who have found a significant decrease in muscular force production (Burt 
& Twist, 2011; Chen, Nosaka & Tu, 2007; Chen et al, 2009; Marcora & Bosio, 
2007) when EIMD is present, with the protocol used to elicit EIMD identical to that 
used by Marcora & Bosio (2007) and Burt & Twist (2011). A possible explanation 
for the contrast in findings could be attributed to the differing standards of 
participants with well-trained runners taking part in this study in comparison to 
moderately trained participants used by Marcora & Bosio (2007) and recreational 
participants used by Burt &Twist (2011). A possible mechanism responsible for 
these differences in muscular force production is the repeated bout affect; with 
McHugh (2003) suggesting those athletes with greater training experience are less 
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susceptible to EIMD in comparison to their counterparts due to this mechanism. 
The repeated bout effect refers to the prior exposure of eccentric loading whereby 
the muscle undergoes structural damage; specifically to the sarcomere length 
resulting in a shorter length adopted preventing such high levels of damage on 
completion of future bouts of exercise (Eston et al, 2003; Falvo & Bloomer, 2006; 
Tee et al, 2007). However the onset of muscle soreness still occurs despite this 
structural change (Tee et al, 2007) as observed during this study. Previous 
research has questioned the use of muscle soreness as a primary measure to 
identify the extent of muscle damage due to a delay in the onset of muscle 
soreness that is preceded by function impairment and followed by greater damage 
when the soreness has subsided (Byrne et al, 2004). This explains the common 
agreement within research that muscular force production is the optimal muscle 
damage marker (Warren et al, 2009) and has the greatest relation to sporting 
performance. Due to a non-significant difference in force production within this 
study a different mechanism must be responsible for the decline in running speed 
and 5 km completion time.  
This decrease in endurance performance could be attributed to the altered 
perception of effort through the ‘central governor model’. This mechanism protects 
the athlete by signalling the body to terminate the exercise bout in order to prevent 
severe damage occurring and homeostasis failure (Noakes, 2007). The model 
suggests that the brain controls the intensity, at which the exercise is undertaken, 
reducing the neural drive to the muscles. This may have been the cause for the 
reduced speed during the second time trial among the treatment group as they 
aimed to complete the time trial as fast as possible identified by a similar RPE 
however, the neural drive to the muscles may have been reduced by the central 
nervous system to protect the participants from further damage. A recent study 
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has shown that over shorter distance time-trials fatigue is more peripherally based 
compared to longer time-trials where central fatigue is of greater dominance in 
cycling (Thomas, Goodall, Stone, Howatson, Gibson & Ansley, 2014). The 
shortest time-trial (4 km) was of a similar distance to that used within this study, 
however due to the significant differences in locomotion speed between cycling 
and running the completion times are significantly different, with the 20km 
completion time closer to the times observed within this study. The findings of 
Thomas et al. (2014) suggest that the fatigue experienced by these well-trained 
runners could be attributed to central more so than peripheral linking to the 
‘central governor model’. Although this study was conducted in cycling and a non-
EIMD state, the findings could help provide some insights into which method of 
fatigue is of dominance during runners after a bout of muscle damaging exercise. 
A similar mechanism has been proposed previously by Marcora & Bosio (2007) 
referring to the requirement of an elevated central motor command to enable 
participants with EIMD and subsequently weaker muscles to maintain similar 
running speeds. The intensity at which participants are able to maintain may also 
be effected by the inflammatory response that impacts the brain, in particular 
cytokines such as interleukin (IL)-1 causing central fatigue. The presence of IL-1 in 
the cortex and cerebellum has been shown to impair endurance performance in 
mice under EIMD (Carmichael et al, 2005) and could explain the observed 
impairment in endurance performance, specifically among male runners during a 
time-trial (Marcora & Bosio, 2007). 
The ambient conditions were a unique variable that could have affected the results 
of the study due to its uncontrollable nature although these helped make the study 
novel. To try keep the ambient conditions as similar as possible for each 
participant the testing occurred within a 3 month period. Another factor that could 
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have implications on the result is the wide age range of the participants, however 
they all met the selection criteria, primarily well-trained and had similar VO2peaks. 
The diet of the participants around the testing could have affected the results too, 
with caffeine consumption (Abu-Kasim & Chen, 2013) and hydration levels 
(Murray, 2013) two aspects that could significantly alter performance. 
Future research could attempt to analyse the effect of EIMD on endurance 
performance at varying time points, possibly 24, 48 and 72 hours providing in 
depth information regarding the recovery over time. Future research could also 
attempt to assess how EIMD affects endurance performance among females and 
any differences that exist between genders. 
This is the first study to assess the effect of EIMD on outdoor endurance 
performance, in particular running. The findings illustrate that EIMD significantly 
effects endurance performance among well-trained athletes primarily through an 
altered perception of effort, supporting previous research that has been conducted 
within a controlled laboratory using recreational participants. Coaches and 
athletes should be aware of these findings regarding the effect programming 
plyometric type activity will have on performance in subsequent days even if their 
athletes are well-trained. 
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Appendix A 
INFORMED CONSENT FORM 
 
Title of Project: The effect of exercise‐induced muscle damage (EIMD) on outdoor running 
performance 
Name of Researcher: Oliver Graham 
Please tick the box if you agree with the statement:  
 
I confirm that I have read and understood the participant information sheet 
for the above‐named study, and have had the opportunity to ask the lead 
researcher any questions.            
 
I understand that my participation is voluntary, and that I am free to withdraw 
from participating in the study at any time, without giving any reason and 
without my rights being affected.  
 
I agree to take part in the above study. 
 
 
Name of Participant      Date       Signature  
 
N/A 
Name of Person taking consent  Date       Signature  
(if different from researcher)  
 
Oliver Graham 
Name of Researcher       Date       Signature  
(1 for participant; 1 for researcher) 
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Appendix B 
Participant Information Sheet 
 
Title of the study: The effect of exercise-induced muscle damage (EIMD) on outdoor 
running performance  
 
Dear participant, 
You  are  being  invited  to  participate  in  a  research  study.  Prior  to  agreeing  to  participate,  it  is 
important for you to understand why the research  is being done and what  it will  involve. Please 
take time to read the following information carefully and discuss it with others if you wish. Please 
feel free to ask me if there is anything that is not clear or if you would like more information. Take 
time to decide whether or not you wish to take part.  
Thank you for reading this. 
What is the purpose of the study? 
The purpose of  this study  is  to assess  the effect EIMD has on outdoor  running performance,  in 
particular 5km. The results from this applied study will help coaches and athletes to understand 
the  effect  a  high  intensity  training  session  that  causes  EIMD  has  on  the  ability  to  train  in 
subsequent days. 
Why have I been chosen? 
You  have  been  selected  to  participate  in  this  study  as  you  meet  the  criteria  required.  The 
participants must be of male sex and be ‘run trained’ whereby they have been running 3 times a 
week for the past 6 months to a year. 
Do I have to take part? 
It is up to you to decide whether or not to take part.  If you decide to take part you will be given 
this information sheet to keep and be asked to sign a consent form.  If you decide to take part you 
are still free to withdraw at any time and without giving a reason.  A decision to withdraw at any 
time, or a decision not to take part, will not affect the standard of care you receive in any way. 
What will happen to me if I take part? 
The study will require you to visit the University of Chester 3 times. On your first visit you will be 
required  to  complete a VO2max  test on a  treadmill  in  the  laboratory and a habituation of  the 
protocol used to measure muscle damage. Within 2 weeks you will be required to complete your 
second visit, which will require you to have muscle damage measurements taken and complete a 
5km run outdoors along the cycle path towards North Wales. If you are selected to be part of the 
experimental  group,  after  the  5km  you will be  required  to  complete  a  bout of plyometrics  to 
cause muscle damage. Then 48 hours later you will be required to complete the same process as 
the second visit without the plyometrics. 
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What are the possible disadvantages and risks of taking part? 
This study will require you to push yourself to exhaustion, which will be uncomfortable. You will 
also be required to give a blood sample  for blood  lactate analysis during your second and third 
visits. 
What are the possible benefits of taking part? 
The benefits of participating in this study are that you will be able to find out your VO2max, which 
you may use for future training programmes to improve your performance along with being part 
of a novel study. 
What if something goes wrong? 
If  you  wish  to  complain  or  have  any  concerns  about  any  aspect  of  the  way  you  have  been 
approached or  treated during  the course of  this study, please contact Professor Sarah Andrew, 
Dean of the Faculty of Applied and Health Sciences, University of Chester, Parkgate Road, Chester, 
CH1 4BJ, 01244  513055. 
If  you  are  harmed  by  taking  part  in  this  research  project,  there  are  no  special  compensation 
arrangements.    If you are harmed due  to  someone’s negligence  (but not otherwise),  then you 
may have grounds for legal action, but you may have to pay for this.   
Will my taking part in the study be kept confidential? 
All information which is collected about you during the course of the research will be kept strictly 
confidential  so  that  only  the  researcher  carrying  out  the  research  will  have  access  to  such 
information. All data will be coded to ensure your remain anonymous. 
What will happen to the results of the research study? 
The results of this project might be published but any data  included will  in no way be  linked to 
any specific participant. 
You are most welcome to request a copy of the results of the project should you wish. 
The data collected will be securely stored in such a way that only those mentioned above will be 
able to gain access to it.  
Who is organising and funding the research? 
The Department of Sport and Exercise Sciences at  the University of Chester will be  involved  in 
organising and carrying out the study. 
Who may I contact for further information? 
If  you  have  any  questions  about  the  project,  either  now  or  in  the  future,  please  feel  free  to 
contact Oliver Graham (   @chester.ac.uk).   
Thank you for your interest in this research. 
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Appendix C 
DEPARTMENT OF SPORT AND EXERCISE SCIENCES  
UNIVERSITY OF CHESTER 
 
PRE-TEST HEALTH QUESTIONNAIRE 
(Please note that this information will be confidential) 
 
Name.…………………………………………………  DOB.……………  
Age.…………..... 
 
Resting blood pressure (mmHg) .……… /……….  Resting heart rate (b.min-1) 
…………… 
 
Practical/Project 
Title.………………………………………………………………………………………… 
    
Please answer these questions truthfully and completely. The purpose of this 
questionnaire is to ensure that you are fit and healthy enough to participate in this 
laboratory practical/research project. 
Yes No 
1. Have you in the past suffered from a serious illness or accident.   
If Yes, please provide details. 
 
……………………………………………………………………………………………………
……………………………………………………………………………………………………
…………………... 
 
Yes No 
2. Have you consulted your doctor the last 6 months      
If Yes, please provide details 
………………………………………………………………………………………………………………….
…………..………………………………………………………………………………………………………
……………………… 
 
3. Do you suffer, or have you suffered from: 
Yes No 
Asthma        
Diabetes        
30 
Bronchitis        
Epilepsy        
High blood pressure       
 
Yes No 
4. Is there any history of heart disease in your family      
 
Yes No 
5. Are you suffering from any infectious skin diseases, sores,                         
wounds, or blood infections i.e., Hepatitis B, HIV, etc.?                   
If Yes, please provide brief details. 
……………………………………………………………………………………………………
……………………………………………………………………………………………………
…………………… 
 
Yes No 
6. Are you currently taking any medication        
If Yes, please provide details. 
……………………………………………………………………………………………………
……………………………………………………………………………………………………
……………………………………………………………………………………………………
……………………………… 
 
 
Yes No 
7. Are you suffering from a disease that inhibits the sweating process    
 
Yes No 
8. Is there anything to your knowledge that may prevent you from     
participating in the testing that has been outlined to you? 
If Yes, please provide details. 
………………………………………………………………………………………………………
………………………………………………………………………………………………………
………………………………………………………………………………………………………
……………………………… 
 
Your Recent Condition 
          Yes No 
 Have you eaten in the last 2 hours?        
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If Yes, please provide details 
……………………………………………………………………………………………………
……………………………………………………………………………………………………
…………………… 
 Evaluate your diet over the last two days.  Poor     Average      Good       
Excellent 
Yes No 
 Have you consumed alcohol in the last 24hr       
Yes No 
 Have you had any kind of illness or infection in the last 2 weeks    
Yes No 
 Have you exercised in the last 2 days?                                                             
  
If Yes, please describe below   
………………………………………………………………………………………………………
………………………………………………………………………………………………………
………………………………………………………………………………………………………
……………………………… 
 
Persons will not be permitted to take part in any experimental testing if they:- 
 have a known history of medical disorders (i.e. hypertension, heart or lung disease) 
 have a fever, suffer from fainting or dizzy spells 
 are currently unable to train because of a joint or muscle injury 
 have had any thermoregulatory disorder 
 have gastrointestinal disorder  
 have a history of infectious diseases (i.e. HIV or Hepatitis B) 
 have, if pertinent to the study, a known history of rectal bleeding, anal fissures, 
haemorrhoids or  any other similar rectal disorder. 
 
My responses to the above questions are true to the best of my knowledge and I 
am assured that they will be held in the strictest confidence. 
 
Name: (Participant)……………………………………………………….
 Date:…………………. 
 
 
Signed (Participant): …………………………………………………… ..  
   
 
 
Name: (Lecturer/technician)…………………………………………….
 Date:…………………. 
 
 
Signed (Lecturer/technician): …………………………………………... 
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Appendix D 
 
 
 
 
 
 
   
Faculty of Applied Sciences 
Research Ethics Committee 
 
frec@chester.ac.uk 
 
 
 
Oliver Sebastian Graham 
Chester 
 
 
 
5th July 2013 
 
 
Dear Oliver, 
 
Study title:  The effect of exercise induced muscle damage (EIMD) on outdoor 
running performance in adult males.       
FREC reference:  810/13/OG/SES 
Version number:  1 
 
Thank  you  for  sending  your  application  to  the  Faculty  of  Applied  Sciences  Research  Ethics 
Committee for review. 
 
I am pleased to confirm ethical approval for the above research, provided that you comply with 
the conditions set out in the attached document, and adhere to the processes described in your 
application form and supporting documentation.  
 
The Committee would like to make the following recommendation:‐ 
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 Remove Q. 7 from the Pre‐test Health Questionnaire 
Please forward an amended copy to frec@chester.ac.uk 
 
The final list of documents reviewed and approved by the Committee is as follows: 
 
Document                        Version  Date 
Application Form                                    1  May 2013 
Appendix 1 – List of References  1  May 2013 
Appendix 2 – C.V. for Lead Researcher  1  May 2013 
Appendix 3 – Letter of Invitation  1  May 2013 
Appendix 4 – Participant Information Sheet  1  May 2013 
Appendix 5 – Participant Consent Form  1  May 2013 
Appendix 6 – Advertisement Material  1  May 2013 
Appendix 7 – Risk Assessment Form  1  May 2013 
Response to FREC request for further information and clarification         June 2013 
Appendix 4 – Participant Information Sheet  2  June 2013 
Appendix 6 – Advertisement Material  2  June 2013 
Appendix 7 – Risk Assessment Form  2  June 2013 
Appendix 8 – Pre‐test Health Questionnaire  1  June 2013 
 
With the Committee’s best wishes for the success of this project.  
 
Yours sincerely, 
 
Dr. Stephen Fallows 
Chair, Faculty Research Ethics Committee 
 
Enclosures:  Standard conditions of approval.   
Cc. Supervisor/FREC Representative 
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Appendix E 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      T1  T2  Trial  Trial x Group 
      M±SD  M±SD  F 
P‐
Value  F 
P‐
Value 
Muscle Circumference  T  53.31 ± 3.515  52.69 ± 4.543  1.51 (1,15)  0.238  0.506 (1,15)  0.488 C  53.39 ± 3.140  53.22 ± 3.032 
Extension Force 
Production  T 
184.625 ± 
17.3455 
176.938 ± 
27.5940  <0.05 
(1,15)  0.999 
2.592 
(1,15)  0.128 
C 
194.333 ± 
28.0485 
202.011 ± 
30.4127 
Flexion Force Production  T  98.950 ± 9.1400  94.225 ± 13.9095  1.418 
(1,15)  0.252 
2.148 
(1,15)  0.163 
C 
104.244 ± 
18.0638 
104.733 ± 
20.6361 
DOMS Quadricep  T  0.38 ± 0.744  2.00 ± 1.690  8.233 
(1,15)  0.012 
0.706 
(1,15)  0.414 C  0.33 ± 1.000  1.22 ± 1.922 
DOMS Hamstring  T  0.88 ± 0.991  3.00 ± 1.690  8.726 
(1,15)  0.01 
8.726 
(1,15)  0.01 C  0  0 
DOMS Calf  T  0.50 ± 1.069  2.38 ± 2.264  7.670 
(1,15)  0.014 
4.764 
(1,15)  0.045 C  0.89 ± 1.833  1.11 ± 2.421 
Average Heart Rate  T  168.88 ± 8.008  170.50 ± 8.718  2.391 
(1,15)  0.143 
0.559 
(1,15)  0.466 C  169.78 ± 12.647  174.44 ± 11.631 
Average RPE  T  16.38 ± 1.061  16.13 ± 1.458  2.233 
(1,15)  0.156 
0.175 
(1,15)  0.682 C  15.67 ± 1.225  15.22 ± 1.093 
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Appendix F 
 
      T1  T2  Trial  Trial x Group  Trial x Group x Distance 
      M±SD  M±SD  F 
P‐
Value  F 
P‐
Value  F  P‐Value 
Heart 
Rate  T 
2.266 (1,15)  0.153 
0.612 
(1,15)  0.446  1.364 (4,60)  0.27 C 
RPE  T 
0.845 (1,15)  0.372 
0.032 
(1,15)  0.861  0.668 (4,60)  0.617 C 
Speed  T 
<0.05 (1,15)  0.989 
0.457 
(1,15)  0.509  2.807 (4,60)  0.033    C       
 
 
 
 
 
 
 
 
